Description | |
h1 tags | The first medication approved by the FDA to treat advanced medullary thyroid cancer (aMTC) The first medication approved by the FDA to treat advanced medullary thyroid cancer (aMTC) About CAPRELSA |
h2 tags | What is CAPRELSA? How CAPRELSA works Why consider CAPRELSA? ZETA Study=331 Patients with aMTC Important Safety Information, including Boxed WARNING, about CAPRELSA |
Site Speed | 0.69523501396179 |
Alexa Rank: |
0 |
Site's Traffic |
Host | Type | Class | TTL | Target |
caprelsa.com | A | IN | 900 | |
caprelsa.com | NS | IN | 900 | ns1.sanofi-synthelabo.com |
caprelsa.com | NS | IN | 900 | ns2.sanofi-synthelabo.com |
caprelsa.com | NS | IN | 900 | ns3.sanofi-synthelabo.com |
caprelsa.com | NS | IN | 900 | ns4.sanofi-synthelabo.com |
caprelsa.com | SOA | IN | 900 | |
caprelsa.com | MX | IN | 900 | mailera.sanofi.com |
caprelsa.com | MX | IN | 900 | mailerb.sanofi.com |
caprelsa.com | TXT | IN | 900 |